Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
July 29, 2022 at 05:22 am EDT
Share
Amoy Diagnostics Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 387.15 million compared to CNY 394.72 million a year ago. Revenue was CNY 392.51 million compared to CNY 398.95 million a year ago. Net income was CNY 89.29 million compared to CNY 111.32 million a year ago. Basic earnings per share from continuing operations was CNY 0.22 compared to CNY 0.28 a year ago. Diluted earnings per share from continuing operations was CNY 0.22 compared to CNY 0.28 a year ago.
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
AMOY DIAGNOSTICS CO., LTD. 
